BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 12941040)

  • 1. Onset of force development as a marker of thrombin generation in whole blood: the thrombin generation time (TGT).
    Carr ME; Martin EJ; Kuhn JG; Spiess BD
    J Thromb Haemost; 2003 Sep; 1(9):1977-83. PubMed ID: 12941040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of platelet contractile force as a research and clinical measure of platelet function.
    Carr ME
    Cell Biochem Biophys; 2003; 38(1):55-78. PubMed ID: 12663942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of recombinant factor VIIa on platelet function and clot structure in blood with deficient prothrombin conversion.
    Carr ME; Martin EJ; Kuhn JG; Seremetis SV
    Thromb Haemost; 2003 May; 89(5):803-11. PubMed ID: 12719776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed, reduced or inhibited thrombin production reduces platelet contractile force and results in weaker clot formation.
    Carr ME; Martin EJ; Carr SL
    Blood Coagul Fibrinolysis; 2002 Apr; 13(3):193-7. PubMed ID: 11943932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of factor VIIa-dependent coagulation in hemophilia blood.
    Butenas S; Brummel KE; Branda RF; Paradis SG; Mann KG
    Blood; 2002 Feb; 99(3):923-30. PubMed ID: 11806995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction.
    Brophy DF; Martin EJ; Best AM; Gehr TW; Carr ME
    J Thromb Haemost; 2004 Aug; 2(8):1299-304. PubMed ID: 15304034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of non-heparin thrombin antagonists on thrombin generation, platelet function, and clot structure in whole blood.
    Carr ME; Angchaisuksiri P; Carr SL; Martin EJ
    Cell Biochem Biophys; 2003; 39(2):89-99. PubMed ID: 14515016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial: 2nd report.
    Shirahata A; Fukutake K; Mimaya J; Takamatsu J; Shima M; Hanabusa H; Takedani H; Takashima Y; Matsushita T; Tawa A; Higasa S; Takata N; Sakai M; Kawakami K; Ohashi Y; Saito H
    Haemophilia; 2013 Mar; 19(2):330-7. PubMed ID: 22989180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients.
    Brophy DF; Martin EJ; Nolte ME; Kuhn JG; Carr ME
    Haemophilia; 2007 Sep; 13(5):533-41. PubMed ID: 17880440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation.
    Gerotziafas GT; Chakroun T; Depasse F; Arzoglou P; Samama MM; Elalamy I
    Thromb Haemost; 2004 May; 91(5):977-85. PubMed ID: 15116259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A.
    Bassus S; Wegert W; Krause M; Escuriola-Ettinghausen C; Siegemund A; Petros S; Scholz T; Scharrer I; Kreuz W; Engelmann L; Kirchmaier CM
    Platelets; 2006 Sep; 17(6):378-84. PubMed ID: 16973498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies.
    Carr ME; Carr SL; Tildon T; Fisher LM; Martin EJ
    J Thromb Haemost; 2003 Feb; 1(2):243-9. PubMed ID: 12871496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
    Gerotziafas GT; Depasse F; Chakroun T; Van Dreden P; Samama MM; Elalamy I
    Blood Coagul Fibrinolysis; 2004 Mar; 15(2):149-56. PubMed ID: 15091002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of markers of coagulation activation and thrombin generation test in uncomplicated pregnancies.
    Joly B; Barbay V; Borg JY; Le Cam-Duchez V
    Thromb Res; 2013 Sep; 132(3):386-91. PubMed ID: 23962423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay.
    Matsumoto T; Shima M; Takeyama M; Yoshida K; Tanaka I; Sakurai Y; Giles AR; Yoshioka A
    J Thromb Haemost; 2006 Feb; 4(2):377-84. PubMed ID: 16420569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of activated partial thromboplastin time clot waveform analysis and thrombin generation test in the evaluation of bleeding phenotype in Hemophilia A.
    Dave RG; Geevar T; Mammen JJ; Vijayan R; Mahasampath G; Nair SC
    Indian J Pathol Microbiol; 2021; 64(1):117-122. PubMed ID: 33433420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant factor VIIa enhances platelet deposition from flowing haemophilic blood but requires the contact pathway to promote fibrin deposition.
    Li R; Panckeri KA; Fogarty PF; Diamond SL
    Haemophilia; 2015 Mar; 21(2):266-274. PubMed ID: 25311576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of action of recombinant activated factor VII in the context of tissue factor concentration and distribution.
    Ovanesov MV; Panteleev MA; Sinauridze EI; Kireev DA; Plyushch OP; Kopylov KG; Lopatina EG; Saenko EL; Ataullakhanov FI
    Blood Coagul Fibrinolysis; 2008 Dec; 19(8):743-55. PubMed ID: 19002040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant factor VIIa does not induce hypercoagulability in vitro.
    Gallistl S; Cvirn G; Muntean W
    Thromb Haemost; 1999 Feb; 81(2):245-9. PubMed ID: 10064000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.